Prospects for prophylactic hepatitis C vaccines based on virus-like particles

References

• Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36:Suppl 1 S35 - 46; http://dx.doi.org/10.1002/hep.1840360706; PMID: 12407575
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44:Suppl S6 - 9; http://dx.doi.org/10.1016/j.jhep.2005.11.004; PMID: 16352363
   PubMed Web of Science ®Google Scholar
• Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17:107 - 15; http://dx.doi.org/10.1111/j.1469-0691.2010.03432.x; PMID: 21091831
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529 - 38; http://dx.doi.org/10.1016/j.jhep.2006.05.013; PMID: 16879891
   PubMed Web of Science ®Google Scholar
• Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55:1350 - 9; http://dx.doi.org/10.1136/gut.2005.076646; PMID: 16905701
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958 - 65; http://dx.doi.org/10.1016/S0140-6736(01)06102-5; PMID: 11583749
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Hézode C, Zeuzem S, Pawlotsky J-M. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56:Suppl 1 S88 - 100; http://dx.doi.org/10.1016/S0168-8278(12)60010-5; PMID: 22300469
   PubMed Web of Science ®Google Scholar
• Edlin BR. Perspective: test and treat this silent killer. Nature 2011; 474:S18 - 9; http://dx.doi.org/10.1038/474S18a; PMID: 21613999
   PubMed Web of Science ®Google Scholar
• Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42:962 - 73; http://dx.doi.org/10.1002/hep.20819; PMID: 16149085
   PubMed Web of Science ®Google Scholar
• Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 2009; 136:2377 - 86; http://dx.doi.org/10.1053/j.gastro.2009.02.080; PMID: 19303013
   PubMed Web of Science ®Google Scholar
• Fuller MJ, Shoukry NH, Gushima T, Bowen DG, Callendret B, Campbell KJ, et al. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology 2010; 51:378 - 87; http://dx.doi.org/10.1002/hep.23319; PMID: 19918975
   PubMed Web of Science ®Google Scholar
• Liu L, Fisher BE, Dowd KA, Astemborski J, Cox AL, Ray SC. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol 2010; 84:5067 - 77; http://dx.doi.org/10.1128/JVI.02265-09; PMID: 20200239
   PubMed Web of Science ®Google Scholar
• Lucas M, Ulsenheimer A, Pfafferot K, Heeg MHJ, Gaudieri S, Grüner N, et al. Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One 2007; 2:e649; http://dx.doi.org/10.1371/journal.pone.0000649; PMID: 17653276
   PubMed Web of Science ®Google Scholar
• Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, et al. Cross-genotype immunity to hepatitis C virus. J Virol 2004; 78:1575 - 81; http://dx.doi.org/10.1128/JVI.78.3.1575-1581.2004; PMID: 14722311
   PubMed Web of Science ®Google Scholar
• Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138:315 - 24; http://dx.doi.org/10.1053/j.gastro.2009.09.017; PMID: 19782080
   PubMed Web of Science ®Google Scholar
• Alvarez-Lajonchere L, Dueñas-Carrera S. Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development. Int Rev Immunol 2012; 31:223 - 42; http://dx.doi.org/10.3109/08830185.2012.680552; PMID: 22587022
   PubMed Web of Science ®Google Scholar
• Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98:706 - 14; http://dx.doi.org/10.1172/JCI118842; PMID: 8698862
   PubMed Web of Science ®Google Scholar
• Pape GR, Gerlach TJ, Diepolder HM, Grüner N, Jung MC, Santantonio T. Role of the specific T-cell response for clearance and control of hepatitis C virus. J Viral Hepat 1999; 6:Suppl 1 36 - 40; http://dx.doi.org/10.1046/j.1365-2893.1999.00006.x; PMID: 10760033
   PubMed Web of Science ®Google Scholar
• Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprowicz V, Nolan BE, Streeck H, et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 2012; 209:61 - 75; http://dx.doi.org/10.1084/jem.20100388; PMID: 22213804
   PubMed Web of Science ®Google Scholar
• Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197:1645 - 55; http://dx.doi.org/10.1084/jem.20030239; PMID: 12810686
   PubMed Web of Science ®Google Scholar
• Puig M, Mihalik K, Tilton JC, Williams O, Merchlinsky M, Connors M, et al. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology 2006; 44:736 - 45; http://dx.doi.org/10.1002/hep.21319; PMID: 16941702
   PubMed Web of Science ®Google Scholar
• Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset FL, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 2007; 104:6025 - 30; http://dx.doi.org/10.1073/pnas.0607026104; PMID: 17392433
   PubMed Web of Science ®Google Scholar
• Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis 2012; 205:763 - 71; http://dx.doi.org/10.1093/infdis/jir835; PMID: 22293431
   PubMed Web of Science ®Google Scholar
• Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005; 79:6023 - 34; http://dx.doi.org/10.1128/JVI.79.10.6023-6034.2005; PMID: 15857988
   PubMed Web of Science ®Google Scholar
• Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 2004; 101:10149 - 54; http://dx.doi.org/10.1073/pnas.0403519101; PMID: 15220475
   PubMed Web of Science ®Google Scholar
• Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design. Expert Opin Ther Pat 2011; 21:1811 - 30; http://dx.doi.org/10.1517/13543776.2011.630662; PMID: 22022980
   PubMed Web of Science ®Google Scholar
• Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11:791 - 6; http://dx.doi.org/10.1038/nm1268; PMID: 15951748
   PubMed Web of Science ®Google Scholar
• Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 2011; 239:99 - 108; http://dx.doi.org/10.1111/j.1600-065X.2010.00977.x; PMID: 21198667
   PubMed Web of Science ®Google Scholar
• Feinstone SM, Hu DJ, Major ME. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus. Clin Infect Dis 2012; 55:Suppl 1 S25 - 32; http://dx.doi.org/10.1093/cid/cis362; PMID: 22715210
   PubMed Web of Science ®Google Scholar
• Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities. Expert Opin Ther Pat 2012; 22:391 - 415; http://dx.doi.org/10.1517/13543776.2012.673589; PMID: 22455502
   PubMed Web of Science ®Google Scholar
• Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 2011; 54:1273 - 85; http://dx.doi.org/10.1016/j.jhep.2010.09.040; PMID: 21236312
   PubMed Web of Science ®Google Scholar
• Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 1994; 91:1294 - 8; http://dx.doi.org/10.1073/pnas.91.4.1294; PMID: 7509068
   PubMed Web of Science ®Google Scholar
• Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005; 436:961 - 6; http://dx.doi.org/10.1038/nature04081; PMID: 16107836
   PubMed Web of Science ®Google Scholar
• Meunier J-C, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J, et al. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis 2011; 204:1186 - 90; http://dx.doi.org/10.1093/infdis/jir511; PMID: 21917891
   PubMed Web of Science ®Google Scholar
• Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010; 28:6367 - 73; http://dx.doi.org/10.1016/j.vaccine.2010.06.084; PMID: 20619382
   PubMed Web of Science ®Google Scholar
• Ray R, Meyer K, Banerjee A, Basu A, Coates S, Abrignani S, et al. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis 2010; 202:862 - 6; http://dx.doi.org/10.1086/655902; PMID: 20677942
   PubMed Web of Science ®Google Scholar
• Dahari H, Feinstone SM, Major ME. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 2010; 139:965 - 74; http://dx.doi.org/10.1053/j.gastro.2010.05.077; PMID: 20621699
   PubMed Web of Science ®Google Scholar
• Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008; 14:25 - 7; http://dx.doi.org/10.1038/nm1698; PMID: 18064037
   PubMed Web of Science ®Google Scholar
• Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A 2012; 109:6205 - 10; http://dx.doi.org/10.1073/pnas.1114927109; PMID: 22492964
   PubMed Web of Science ®Google Scholar
• Meunier J-C, Russell RS, Goossens V, Priem S, Walter H, Depla E, et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol 2008; 82:966 - 73; http://dx.doi.org/10.1128/JVI.01872-07; PMID: 17977972
   PubMed Web of Science ®Google Scholar
• Keck ZY, Sung VMH, Perkins S, Rowe J, Paul S, Liang TJ, et al. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol 2004; 78:7257 - 63; http://dx.doi.org/10.1128/JVI.78.13.7257-7263.2004; PMID: 15194801
   PubMed Web of Science ®Google Scholar
• Ralston R, Thudium K, Berger K, Kuo C, Gervase B, Hall J, et al. Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J Virol 1993; 67:6753 - 61; PMID: 8411378
   PubMed Web of Science ®Google Scholar
• Duvet S, Cocquerel L, Pillez A, Cacan R, Verbert A, Moradpour D, et al. Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. J Biol Chem 1998; 273:32088 - 95; http://dx.doi.org/10.1074/jbc.273.48.32088; PMID: 9822684
   PubMed Web of Science ®Google Scholar
• Sominskaya I, Alekseeva E, Skrastina D, Mokhonov V, Starodubova E, Jansons J, et al. Signal sequences modulate the immunogenic performance of human hepatitis C virus E2 gene. Mol Immunol 2006; 43:1941 - 52; http://dx.doi.org/10.1016/j.molimm.2005.11.018; PMID: 16442623
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Batens A-H, Desombere I, Van Den Steen B, Vander Stichele C, Maertens G, et al. Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum Vaccin 2005; 1:61 - 5; http://dx.doi.org/10.4161/hv.1.2.1554; PMID: 17038823
   PubMed Web of Science ®Google Scholar
• McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307:178 - 80; http://dx.doi.org/10.1038/307178a0; PMID: 6318124
   PubMed Web of Science ®Google Scholar
• Muñoz N, Manalastas R Jr., Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373:1949 - 57; http://dx.doi.org/10.1016/S0140-6736(09)60691-7; PMID: 19493565
   PubMed Web of Science ®Google Scholar
• Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 1998; 72:3827 - 36; PMID: 9557666
   PubMed Web of Science ®Google Scholar
• Baumert TF, Vergalla J, Satoi J, Thomson M, Lechmann M, Herion D, et al. Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology 1999; 117:1397 - 407; http://dx.doi.org/10.1016/S0016-5085(99)70290-8; PMID: 10579981
   PubMed Web of Science ®Google Scholar
• Triyatni M, Vergalla J, Davis AR, Hadlock KG, Foung SKH, Liang TJ. Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology 2002; 298:124 - 32; http://dx.doi.org/10.1006/viro.2002.1463; PMID: 12093180
   PubMed Web of Science ®Google Scholar
• Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 2001; 34:417 - 23; http://dx.doi.org/10.1053/jhep.2001.26523; PMID: 11481628
   PubMed Web of Science ®Google Scholar
• Jeong S-H, Qiao M, Nascimbeni M, Hu Z, Rehermann B, Murthy K, et al. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol 2004; 78:6995 - 7003; http://dx.doi.org/10.1128/JVI.78.13.6995-7003.2004; PMID: 15194776
   PubMed Web of Science ®Google Scholar
• Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A 2003; 100:6753 - 8; http://dx.doi.org/10.1073/pnas.1131929100; PMID: 12748380
   PubMed Web of Science ®Google Scholar
• Elmowalid GA, Qiao M, Jeong S-H, Borg BB, Baumert TF, Sapp RK, et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A 2007; 104:8427 - 32; http://dx.doi.org/10.1073/pnas.0702162104; PMID: 17485666
   PubMed Web of Science ®Google Scholar
• Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197:633 - 42; http://dx.doi.org/10.1084/jem.20021756; PMID: 12615904
   PubMed Web of Science ®Google Scholar
• Gottwein JM, Scheel TKH, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009; 49:364 - 77; http://dx.doi.org/10.1002/hep.22673; PMID: 19148942
   PubMed Web of Science ®Google Scholar
• Ludwig C, Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 2007; 18:537 - 45; http://dx.doi.org/10.1016/j.copbio.2007.10.013; PMID: 18083549
   PubMed Web of Science ®Google Scholar
• Bartosch B, Dubuisson J, Cosset F-L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197:633 - 42; http://dx.doi.org/10.1084/jem.20021756; PMID: 12615904
   PubMed Web of Science ®Google Scholar
• Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, Blackwelder WC, et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 2003; 100:14199 - 204; http://dx.doi.org/10.1073/pnas.2335981100; PMID: 14617769
   PubMed Web of Science ®Google Scholar
• Garrone P, Fluckiger A-C, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 2011; 3:94ra71; http://dx.doi.org/10.1126/scitranslmed.3002330; PMID: 21813755
   PubMed Web of Science ®Google Scholar
• Huret C, Desjardins D, Miyalou M, Levacher B, Amadoudji Zin M, Bonduelle O, et al. Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice. Vaccine [Internet] 2012 [cited 2013 Jan 16]; Available from: http://linkinghub.elsevier.com/retrieve/pii /S0264410X12007293.
   Google Scholar
• Mihailova M, Boos M, Petrovskis I, Ose V, Skrastina D, Fiedler M, et al. Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine 2006; 24:4369 - 77; http://dx.doi.org/10.1016/j.vaccine.2006.02.051; PMID: 16574285
   PubMed Web of Science ®Google Scholar
• Sominskaya I, Skrastina D, Dislers A, Vasiljev D, Mihailova M, Ose V, et al. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes. Clin Vaccine Immunol 2010; 17:1027 - 33; http://dx.doi.org/10.1128/CVI.00468-09; PMID: 20410327
   PubMed Web of Science ®Google Scholar
• Lee IH, Kim CH, Ryu WS. Presentation of the hydrophilic domains of hepatitis C viral E2 envelope glycoprotein on hepatitis B surface antigen particles. J Med Virol 1996; 50:145 - 51; http://dx.doi.org/10.1002/(SICI)1096-9071(199610)50:2<145::AID-JMV7>3.0.CO;2-A; PMID: 8915880
   PubMed Web of Science ®Google Scholar
• Netter HJ, Macnaughton TB, Woo WP, Tindle R, Gowans EJ. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol 2001; 75:2130 - 41; http://dx.doi.org/10.1128/JVI.75.5.2130-2141.2001; PMID: 11160717
   PubMed Web of Science ®Google Scholar
• Vietheer PTK, Boo I, Drummer HE, Netter H-J. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. Antivir Ther 2007; 12:477 - 87; PMID: 17668556
   PubMed Web of Science ®Google Scholar
• Patient R, Hourioux C, Vaudin P, Pagès JC, Roingeard P. Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies. N Biotechnol 2009; 25:226 - 34; http://dx.doi.org/10.1016/j.nbt.2009.01.001; PMID: 19356608
   PubMed Web of Science ®Google Scholar
• Beaumont E, Patient R, Hourioux C, Dimier-Poisson I, Roingeard P. Chimeric HBV-HCV envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. Hepatology [Internet] 2012 [cited 2013 Jan 16]; Available from: http://onlinelibrary.wiley.com/doi/10.1002/hep.26132/abstract
   Google Scholar
• Denis J, Majeau N, Acosta-Ramirez E, Savard C, Bedard MC, Simard S, et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology 2007; 363:59 - 68; http://dx.doi.org/10.1016/j.virol.2007.01.011; PMID: 17320136
   PubMed Web of Science ®Google Scholar
• Michel ML, Mancini M, Sobczak E, Favier V, Guetard D, Bahraoui EM, et al. Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV--hepatitis B surface antigen particles. Proc Natl Acad Sci U S A 1988; 85:7957 - 61; http://dx.doi.org/10.1073/pnas.85.21.7957; PMID: 2460859
   PubMed Web of Science ®Google Scholar
• Berkower I, Spadaccini A, Chen H, Al-Awadi D, Muller J, Gao Y, et al. Hepatitis B virus surface antigen assembly function persists when entire transmembrane domains 1 and 3 are replaced by a heterologous transmembrane sequence. J Virol 2011; 85:2439 - 48; http://dx.doi.org/10.1128/JVI.02061-10; PMID: 21177825
   PubMed Web of Science ®Google Scholar
• Phogat S, Svehla K, Tang M, Spadaccini A, Muller J, Mascola J, et al. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology 2008; 373:72 - 84; http://dx.doi.org/10.1016/j.virol.2007.11.005; PMID: 18155743
   PubMed Web of Science ®Google Scholar
• Strickland GT, El-Kamary SS, Klenerman P, Nicosia A. Hepatitis C vaccine: supply and demand. Lancet Infect Dis 2008; 8:379 - 86; http://dx.doi.org/10.1016/S1473-3099(08)70126-9; PMID: 18501853
   PubMed Web of Science ®Google Scholar
• Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006; 12:190 - 7; http://dx.doi.org/10.1038/nm1353; PMID: 16462801
   PubMed Web of Science ®Google Scholar
• Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012; 4:ra1; http://dx.doi.org/10.1126/scitranslmed.3003155; PMID: 22218690
   PubMed Web of Science ®Google Scholar